Role of positron emission tomography using fluorine-18 fluoro-2-deoxyglucose in predicting improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy

European Journal of Nuclear Medicine

Volumn 25, Issue 7, 1998, Pages 736-743

  Yokoyama, Ikuo ^a   Momomura, Shin Ichi ^a   Ohtake, Tohru ^a   Yonekura, Katsunori ^a   Inoue, Yusuke ^a   Kobayakawa, Naoshi ^a   Aoyagi, Teruhiko ^a   Sugiura, Seiryo ^a   Nishikawa, Jun Ichi ^a   Sasaki, Yasuhito ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fluorine 18 fluoro 2 deoxyglucose; Idiopathic dilated cardiomyopathy; Left ventricular function; Myocardial glucose utilization; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GLUCOSE UTILIZATION; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS;

ADULT; AGED; CARDIOMYOPATHY, DILATED; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RADIOPHARMACEUTICALS; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; VENTRICULAR FUNCTION, LEFT;

EID: 7344257739     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050277     Document Type: Article

References (31)

1. Goodwill JF, Gordon H, Hollman A, Bishop MB: Clinical aspects of cardiomyopathy. Br Med J 1961; I: 69-79.
2. Parrillo JE, Aretz HT, Palacios I, et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial disease in patients with idiopathic heart failure. Circulation 1984; 69: 93-101.
3. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one year mortality of dilated cardiomyopathy. Am J Cardiol 1984; 54: 147-152.
4. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
5. Heck CF, Shumway SJ, Kaye MP. The Registry of the International Society tor Heart Transplantation. Sixth official report 1989. J Heart Transplant 1989; 8: 271-276.
6. Evans RW, Manninen DL, Garrison LP, Maier AM. Donor availability as the primary determinant of the future of heart transplantation. JAMA 1986; 255: 1892-1898.
7. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
8. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hajamarson A. Long-term β-bockade in dilated cardiomyopathy: effect of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551-563.
9. Ikram H, Fitzpartrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; II: 490-492.
10. Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J, Anderson ST, Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984; 3: 203-209.
11. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-2825.
12. Packer M, Colucci WS, Sackner Bernstein JD, et al. Double blind placebo-controlled study of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation 1996; 94: 2793-2799.
13. Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980; 302: 1373-1379.
14. The CONSENSUS Trial Study Group. Effects of enarapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
16. Figulla HR, Gietzen F, Zymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of diltiazem in the Dilated Cardiomyopathy Trial. Circulation 1996; 94: 346-352.
17. Wynne J, Braunwald E. The cardiomyopathy and myocarditis: toxic, chemical, and physical damage to the heart. In: Heart disease, 4th edn. Philadelphia: Saunders; 1992: 1398. Braunwald E ed.
18. Burkley BH, Huchins GM, Bailey I, Strauss HW, Pitt B. Thallium 201 imaging and gated cardiac scans in patients with ischemic and idiopathic cardiomyopathy. Circulation 1977; 55: 753-760.
19. Doi YL, Chikamori T, Tukata J, et al. Prognostic value of thallium 201 perfusion defects in idiopathic dilated cardiomyopathy and severe coronary artery disease. Am J Cardiol 1991; 67: 188-193.
20. Merlet P. Prognostic value of cardiac metaiodobenzyl guanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477
21. Fukuoka S, Hayashida K, Hirose Y, et al. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 1997; 24: 523-529.
22. Suwa M, Ohtake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopthy. Am Heart J 1997; 133: 353-358.
23. 14C) deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
24. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood to brain transfer contents from multiple time uptake data. J Cereb Blood Flow Metab 1985; 5: 584-590.
25. Phelps ME, Hoffman EJ, Selin CE, et al. Investigation of (F-18)2-fluoro-2-deoxyglucose for the measurement of myocardial glucose metabolism. J Nucl Med 1978; 19: 1311-1319.
26. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991; 32: 1432-1438.
27. Gambhir SS, Schwaiger M, Huang SC, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18-deoxyglucose. J Nucl Meb 1989; 30: 359-366.
28. Nishikawa J, Ohtake T, Yokoyama I, et al. Simple method to quantify myocardial glucose metabolism from MB ratio in myocardial FDG PET. Ann Nucl Med 1996; 10: 323-328.
29. Ehrenkaufer RE, Potocki JF, Jewett DM, et al. Simple synthesis of F-18 labeled 2-fluoro-2-deoxy-D-glucose. J Nucl Med 1989; 26: 477-485.
30. Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy. Circulation 1985; 71: 1095-1104.
31. Kurozumi H, Yokota Y, Nomura H, et al. Obsevation of dilated cardiomyopathy with marked clinical improvement. J Cardiol 1988; 18: 1027-1031.